Even with the slowdown in dealmaking among European venture investors, VCs are demonstrating a relatively strong appetite for startups in the life sciences sector.

VC has been a major driver of innovation in the sector, fueling the development of breakthrough therapies, medical devices and diagnostic tools. With the potential for significant returns on investment and a steady stream of promising scientific discoveries, investments have accelerated in recent years, particularly with the pandemic.

Dealmaking slowed last year amid a wider global downturn. However, Europe's life sciences startups managed to attract €6.4 billion (about $7.1 billion) across 816 rounds, according to PitchBook data. So far in 2023, 180 deals have closed worth a total of €1.8 billion. This includes Amolyt Pharma's €130 million Series C led by Sofinnova Partners and ICG as well as Hemab Therapeutics' $135 million Series B led by Access Biotechnology.

Here are the 10 most active investors in European life sciences VC deals since 2017, according to PitchBook data.
 
 

Featured image by Prasert Sripodok/Shutterstock 

You can unsubscribe at any time by clicking on the unsubscribe link at the bottom of our emails. Please refer to our privacy policy or contact us for more details.

Related content